Ultra-LEAF™ Purified anti-human CD20 (Rituximab Biosimilar, RUO) Recombinant Antibody, CD20, QA20A02,BioLegend,378004

This recombinant antibody is based on the published sequence for the Rituximab antibody. This product is for research use only. It is not intended for therapeutic or diagnostic purposes.

Host

Human

Reactivity

Human

Application

FC - Quality testedCMCD - Verified

Platform ID

BAB877292015

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

BioLegend

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameUltra-LEAF™ Purified anti-human CD20 (Rituximab Biosimilar, RUO) Recombinant Antibody, CD20, QA20A02
Cat. No.378004
HostHuman
RRIDAB_2924569 (BioLegend Cat. No. 378003)AB_2924569 (BioLegend Cat. No. 378004)
IsotypeHuman IgG1, κ
ReactivityHuman
ApplicationFC - Quality testedCMCD - Verified
ClonalityRecombinant
Clone NumberQA20A02
ConcentrationThe antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration, please enter the lot number in ourConcentration and Expiration LookuporCertificate of Analysisonline tools.
TargetCD20
ImmunogenHuman CD20
PurityThe Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Formulation150 mM sodium chloride, pH 6.5
StorageThe antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Regulatory StatusResearch Use Only

Scientific Background

CD20 is a surface marker expressed on B lymphocytes. CD20 is a 33-37 kD protein with four hydrophobic transmembrane domains that it associates with cell-surface and cytoplasmic proteins such as CD53, CD81, CD82, MHCII, CD40, CBP, and BCR. This association contributes to signal transduction essential for the development, differentiation, and activation of B cells. CD20 is also variably expressed by B cell malignancies such as Chronic lymphocytic leukemia (CLL), follicular lymphoma, and diffuse large B-cell lymphoma (DLBCL).

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.